Andrew L. Mason MBBS, FRCPI, FAASLDProfessor of Medicine, Division of Gastroenterology; Director, The Applied Genomic Core, Faculty of Medicine and Dentistry; Co-Director, Center of Excellence for Gastrointestinal Inflammation and Immunity Research, University of Alberta, Edmonton, Alberta, Canada
Dr. Mason is Professor of Medicine in the Division of Gastroenterology at the University of Alberta, Edmonton, Alberta. He is Director of the Applied Genomics Core in the Faculty of Medicine and Dentistry, Director of Gastrointestinal and Liver Disease Research, and Co-Director of the Center of Excellence for Gastrointestinal Inflammation and Immunity Research.
Dr. Mason has established a translational research program studying the role of a human betaretrovirus in patients with primary biliary cholangitis. The Mason laboratory currently evaluates different antiretroviral therapies in a mouse model of autoimmune biliary disease with betaretrovirus cholangitis. His group are currently developing diagnostic assays to detect immune responses to betaretrovirus infection in patients with autoimmune liver disease. He is Principal Investigator on a Canadian multi-center, randomized controlled trial assessing combination anti-retroviral therapy for patients with primary biliary cholangitis, and Co-Principal Investigator for the Canadian Network for Autoimmune Liver Disease studying demographic and prognostic features of primary biliary cholangitis and autoimmune hepatitis.